🧬Molecule of the Moment | #Nivolumab
FDA approves nivolumab (Opdivo) + AVD for untreated Stage III/IV classical Hodgkin lymphoma (≥12 yrs).

MedChemExpress’s nivolumab has been cited in 22 publications, supporting scientific research. For research use only. medchemexpress.com/Anti-PD-1_Ne...

Ipilimumab Plus Nivolumab With Chemoradiotherapy Leads to Bladder Preservation in Urothelial Carcinoma of the Bladder | OncLive Induction ipilimumab plus nivolumab followed by consolidative chemoradiotherapy led to bladder preservation in stage 2/3 urothelial carcinoma of the bladder.

🧪 Induction #Ipilimumab + #Nivolumab followed by chemoradiotherapy achieved 78% 2-yr bladder-intact event-free survival and strong OS signals in the INDIBLADE trial 👏 📈 @ascocancer.bsky.social #GU26 #oncology Read more➡️ www.onclive.com/view/ipilimu...

Cytomegalovirus gastritis following immune checkpoint inhibitor-associated gastritis induced by ipilimumab and nivolumab therapy in a patient with renal cell carcinoma A case of immune-related gastritis complicated by subsequent cytomegalovirus gastritis in a patient undergoing combination therapy with ipilimumab and nivolumab for renal cell carcinoma.

#MedCase - A case of immune-related #gastritis complicated by subsequent CMV #gastritis in a patient undergoing combination therapy with #ipilimumab and #nivolumab for renal cell carcinoma.

👉 buff.ly/oaquChZ

#OncSky

The combination of brentuximab vedotin and #nivolumab with #chemotherapy produced strong responses in treatment-naïve, non-bulky, early-stage classical #Hodgkin #lymphoma, with an ORR of 96% and estimated two-year PFS of 97% seen in study participants: https://ow.ly/lIQL50Yh9cy
#HemeSky #OncSky

Les scientifiques ont découvert qu’un médicament d’#Immunothérapie contre le #Cancer approuvé par la #FDA le " #Nivolumab / #Relatlimab" bloque la progression de la maladie de #Parkinson en empêchant la propagation de protéines cérébrales toxiques qui causent des lésions neuronales

Chronotherapy and Nivolumab in Metastatic Gastric Cancer: Does Infusion Timing Matter? - OncoDaily Chronotherapy nivolumab may improve outcomes in metastatic gastric cancer, with earlier infusion timing linked to better response and survival.

Chronotherapy and Nivolumab in Metastatic Gastric Cancer: Does Infusion Timing Matter?

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Chronotherapy #Nivolumab #GastricCancer #GIOnc

Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: Insights From the GUARDIANS Multicenter Cohort - OncoDaily Real-world data show ipilimumab + nivolumab provides meaningful survival benefits in advanced Renal Cell Carcinoma, with outcomes shaped by risk, histology, and toxicity.

Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: Insights From the GUARDIANS Multicenter Cohort

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Ipilimumab #Nivolumab #RenalCellCarcinoma #RCC

The Future of Atypical Teratoid/Rhabdoid Tumor Treatment Market Looks Bright with Expanding Research Initiatives The Atypical Teratoid/Rhabdoid Tumor market is set to grow significantly thanks to molecular diagnostics and promising new therapies targeting this aggressive pediatric cancer.

The Future of Atypical Teratoid/Rhabdoid Tumor Treatment Market Looks Bright with Expanding Research Initiatives #United_States #Las_Vegas #Nivolumab #Atypical_Tumor #Alisertib

CA209-7AL, a #ClinicalTrial evaluating the efficacy & safety of consolidative #Nivolumab (NIVO) Vs observation following #neoadjuvant NIVO + #chemotherapy & concurrent #Chemoradiotherapy reveals both efficacy & tolerability in stage III #NSCLC.

Read: doi.org/10.1038/s413...

Measures · Uptake of nivolumab subcutaneous | OpenPrescribing Hospitals What is this measure?

Didn't get a chance to mention it at yesterday's #BOPA2025 SC #Nivolumab session...

The amazing guys at #OpenPrescribing have built a SC Nivo tracker. Want to know if you are ahead of the cure - check this out:

hospitals.openprescribing.net/measures/niv...

Triple Combination of Encorafenib, Cetuximab, and Nivolumab in MSS BRAFV600E Metastatic Colorectal Cancer - OncoDaily Triplet of encorafenib, cetuximab, and nivolumab shows 50% response and 22-month OS in MSS BRAFV600E mCRC.

Triple Combination of Encorafenib, Cetuximab, and Nivolumab in MSS BRAFV600E Metastatic Colorectal Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Encorafenib #Cetuximab #Nivolumab #ColorectalCancer #CRC #GIOnc

Perioperative Nivolumab ± Ipilimumab in Resectable Diffuse Pleural Mesothelioma

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Nivolumab #Ipilimumab #IO #DiffusePleuralMesothelioma #Mesothelioma

Cancer treatment times in Bristol halved with Nivolumab injection Patient Karen Thompson says there are

Cancer treatment just got faster!
UHBW is among the first in the UK to use pioneering #Nivolumab injections, halving treatment times while boosting the body’s immune fight against tumours. #CancerResearch #Immunotherapy #TCSC #UHBW #Bristol #Immunesystem

www.bbc.co.uk/news/article...

Partial Response to #Nivolumab and #Ipilimumab in a Patient With Malignant Pleural #Mesothelioma and Pre-Existing #MyastheniaGravis Without Severe Flares or Immune-Related Adverse Events: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...

Neoadjuvant Nivolumab in Resectable Lung Cancer | NEJM Quick Take Video Summary from The New England Journal of Medicine — Neoadjuvant Nivolumab in Resectable Lung Cancer

Neoadjuvant #Nivolumab in Resectable #LungCancer | New England Journal of Medicine www.nejm.org/do/10.1056/N...

10-Minute Immunotherapy Infusion: Safe, Efficient Delivery of Nivolumab and Pembrolizumab - OncoDaily Explore how docus-based 10-minute immunotherapy infusion with nivolumab/pembrolizumab boosts efficiency without compromising safety in oncology care.

10-Minute Immunotherapy Infusion: Safe, Efficient Delivery of Nivolumab and Pembrolizumab

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Immunotherapy #IO #Nivolumab #Pembrolizumab

https://www.cancertherapyadvisor.com/news/sucralose-intake-may-reduce-efficacy-of-icis/

High Sucralose Intake May Reduce Efficacy of ICIs

#nivolumab #pembrolizumab

t.co/jkzshm9b0B

Real-World Study Confirms Nivolumab Plus Cabozantinib Improves Survival in Metastatic RCC - OncoDaily Real-world ARON-1 study confirms nivolumab + cabozantinib improves survival in metastatic RCC, with 75% 2-year OS and strong efficacy in diverse populations.

Real-World Study Confirms Nivolumab Plus Cabozantinib Improves Survival in Metastatic RCC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Nivolumab #Cabozantinib #RCC #RenalCellCarcinoma

Daniel Flora: A Paradigm Shift in Cancer Care - Immunotherapy Before Surgery Delivers Long-Term Survival - OncoDaily Daniel Flora: A Paradigm Shift in Cancer Care - Immunotherapy Before Surgery Delivers Long-Term Survival / Alexander Lazar, cancer, Daniel Flora, Denái R.

A Paradigm Shift in Cancer Care: Immunotherapy Before Surgery Delivers Long-Term Survival - Daniel Flora
@dbfloramd.bsky.social

oncodaily.com/insight/immu...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Immunotherapy #Relatlimab #Nivolumab #Melanoma

Herpes virus could soon be approved to treat severe skin cancer A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma

#Herpes #virus could soon be approved to treat severe #skin #cancer ...

| #melanoma | #RP1 | #nivolumab | #tumours | By @mjflepage.bsky.social via newscientist .com

Cancer-fighting herpes virus combined with immunotherapy shown to be an effective treatment for some advanced melanoma – BioNews Central A genetically engineered herpes simplex virus, combined with immunotherapy, reduces or eliminates tumors in one-third of patients with advanced melanoma. ...

A #GeneticallyEngineered #HerpesSimplexVirus, combined with #immunotherapy, reduces or eliminates #tumors in one-third of patients with #AdvancedMelanoma.
#Melanoma #OncolyticImmunotherapy #Nivolumab #CombinationTherapy

A Case of PMR-Like irAE Developing After Treatment With #Ipilimumab and #Nivolumab for #LungCancer
onlinelibrary.wiley.com/doi/10.1002/...

Arndt Vogel: 1L Nivo Plus Low-Dose Ipi Shows Promising Results in MSI Advanced Gastric Cancer - OncoDaily Arndt Vogel: 1L Nivo Plus Low-Dose Ipi Shows Promising Results in MSI Advanced Gastric Cancer / Akitaka Makiyama, Arndt Vogel, cancer, Esophagogastric

1L Nivo Plus Low-Dose Ipi Shows Promising Results in MSI Advanced Gastric Cancer - Arndt Vogel
@arndtvogel.bsky.social

oncodaily.com/science/nivo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Nivolumab #Ipilimumab #GastricCancer #EsophagogastricJunctionCancer #EGJ

Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.

Nivolumab + relatlimab show promising intracranial activity in melanoma brain metastases! A beacon of hope for resistant cases and a call for more research!
#Melanoma #BrainMetastases #Immunotherapy #Nivolumab #Relatlimab #CheckpointInhibitors #TCSC #Oncology

www.cancernetwork.com/view/nivolum...

Add-on nivolumab could be new standard of care in locally advanced HNSCC Supplementing adjuvant chemoradiotherapy with nivolumab significantly improves the outcomes of patients with locally advanced head and neck squamous cell carcinoma at high risk for recurrence.

From #ASCO25 - Supplementing adjuvant #chemoradiotherapy with #nivolumab significantly improves the outcomes of patients with locally advanced head and neck squamous cell carcinoma at high risk for recurrence.

Full story 👉 buff.ly/NF3ZGok

#MedNews #OncSky

#PublicaSalutIB Hematologia de Son Espases ha participat en un assaig sobre l'ús del Nivolumab i sunitinib en pacients amb sarcomes ossis avançats www.infosalut.com/investigacio/estudis-i-p... https://doi.org/10.1002/cncr.35628

#hematologia #nivolumab #sunitinib #sarcomesossis

#PublicaSalutIB Hematologia de Son Espases ha participado en un ensayo sobre el uso del Nivolumab y sunitinib en pacientes con sarcomas óseos avanzados https://www.infosalut.com/es/17448 https://doi.org/10.1002/cncr.35628
#hematología #nivolumab #sunitinib #sarcomasóseos #cáncer

#PublicaSalutIB Hematologia de Son Espases ha participat en un assaig sobre l'ús del Nivolumab i sunitinib en pacients amb sarcomes ossis avançats www.infosalut.com/investigacio/estudis-i-p... https://doi.org/10.1002/cncr.35628

#hematologia #nivolumab #sunitinib #sarcomesossis

No Limit trial: Results of Nivolumab+Ipilmumab in MSI-H GC Explore NO LIMIT trial's response rate with nivolumab plus low-dose ipilimumab in MSI-H advanced gastric cancer, showing durable clinical benefit.

New Paper Alert: NO LIMIT Trial. First-Line Nivolumab Plus Low-Dose Ipilimumab in MSI-High Advanced Gastric and GEJ Cancer

oncodaily.com/opinion/nivo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NOLIMIT #Nivolumab #Ipilimumab #GEJCancer #GastricCancer

Bilateral optic neuropathy in Krukenberg tumor treated with FOLFOX plus nivolumab: a case report This case highlights the potential for severe bilateral optic neuropathy associated with FOLFOX plus nivolumab treatment, leading to irreversible vision loss.

#MedCase - A 48-year-old woman treated with FOLFOX plus #nivolumab for a Krukenberg tumor developed bilateral optic neuropathy, highlighting the need for close ophthalmologic monitoring in patients receiving this treatment.

👉 buff.ly/NI48RqY

#OncSky #EyeMed #KrukenbergTumor